Solid Biosciences Inc. announced the appointment of Gabriel Brooks, M.D., as Chief Medical Officer. Prior to joining Solid Biosciences, Dr. Brooks was Rare Cardiovascular Therapeutic Area Head in the Rare Disease Research Unit at Pfizer. While there, he directed the translational development of a range of precision AAV gene therapies for dilated, arrhythmogenic, and hypertrophic cardiomyopathies.

Additionally, Dr. Brooks previously served as the vice president of research and development at 4D Molecular Therapeutics, where he oversaw translational development of AAV gene therapies for Anderson Fabry and oversaw first-in-human dosing of AAV gene therapies for two ophthalmologic indications (choroideremia and X-linked retinitis pigmentosa). Previously, Dr. Brooks led a successful Phase III registrational study of flurpiridaz at GE Life Sciences, and led several cardiovascular clinical trials in rare and large market indications while at Gilead Life Sciences. Dr. Brooks received a Bachelor of Science in Biology from Carnegie Mellon University, a Doctor of Medicine from Cornell University and a Master of Applied Sciences of Biostatistics and Epidemiology from the University of California, San Francisco.

He completed his training in Internal Medicine at Johns Hopkins Hospital, Baltimore, and fellowships in general Cardiology and Advanced Imaging at the University of California, San Francisco.